Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Multi-centre, Dose-Evaluation Study of the Efficacy and Safety of TLA Gut™ Leukapheresis Treatment in Patients With Ulcerative Colitis

NCT04550130 is registered in ClinicalTrials.gov with TLA, Targeted Immunotherapies AB as lead sponsor.

NCT NCT04550130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04550130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Multi-centre, Dose-Evaluation Study of the Efficacy and Safety of TLA Gut™ Leukapheresis Treatment in Patients With Ulcerative Colitis
Lead sponsor
TLA, Targeted Immunotherapies AB
Phase
Not applicable
Overall status
Unknown status
Start date
December 31, 2022
Completion date
December 31, 2023
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)